In a recent study published in Science, Zhang et al. discovered that tripartite motif-containing (TRIM) protein 11 (TRIM11) exhibited strong inhibition on tau aggregation, which is a pathological characteristic of tauopathies including Alzheimer’s disease (AD).1 This makes TRIM11 a promising novel target for the treatment of AD and other tauopathies. The gene discussed is MAPT; the disease is tauopathy.